EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Hepatitis B Screening, Antiviral Prophylaxis, and Reactivation Risk in Rituximab-Treated Patients: A 17-Year Population-Based Cohort Study Highlighting Current Practices and Gaps

Fadi Abu Baker, Mifleh Tatour, Ahmad Yehya, Tarek Saadi, Rawi Hazzan

Digestive Diseases and Sciences · 2026

DOI: 10.1007/s10620-026-09998-0 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Digestive Diseases and Sciences, 2026. Verfasst von Fadi Abu Baker und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Hillel Yaffe Medical Center, Hadera, Israel. Hauptthemen laut MEDLINE: Rituximab, Virus Activation, Antiviral Agents, Hepatitis B virus. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bar-Ilan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hepatitis B virus (HBV) reactivation is a potentially severe and preventable complication of immunosuppressive therapy, particularly with anti-CD20 agents such as rituximab, underscoring the need for effective screening and prophylaxis to reduce adverse outcomes. METHODS: We conducted a retrospective population-based cohort study using the Clalit Health Services database in northern Israel. Adult patients aged ≥ 18 years who received rituximab between 2005 and 2022 were included. HBV screening (HBsAg and anti-HBc), antiviral prophylaxis, and HBV reactivation events were evaluated. Timely screening was defined as testing performed within 90 days before rituximab initiation. Temporal trends were analyzed using the Cochran-Armitage test, and predictors of reactivation were evaluated using Cox proportional hazards models, with the per-patient analysis considered the primary model. RESULTS: After exclusion of patients younger than 18 years, a total of 11,888 adult patients received rituximab during the study period (mean age 61.6 ± 15.6 years; 54.7% female). Only 10.5% of patients underwent timely HBV screening before treatment initiation, while 47.4% were never screened without time restriction and 89.5% had no HBV serology within 90 days before rituximab initiation. Among screened patients, approximately 6.0% had evidence of current or prior HBV infection. Screening rates improved significantly over time (P < 0.0001) but remained suboptimal across clinical settings. Antiviral prophylaxis increased over the study period but plateaued at approximately 50% among eligible patients. A total of 159 HBV reactivation events were identified, corresponding to an incidence of 1.06% per treatment event and approximately 1.3% per patient. Reactivation occurred predominantly among patients who had not undergone HBV screening. Multivariable analysis identified male sex as an independent predictor of HBV reactivation. CONCLUSIONS: Despite gradual improvement over nearly two decades, HBV screening before rituximab therapy remains insufficient in real-world clinical practice. Given that HBV reactivation is largely preventable with appropriate screening and antiviral prophylaxis, system-level interventions are needed to improve adherence to guideline-recommended care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabVirus ActivationAntiviral AgentsHepatitis B virusHepatitis BImmunosuppressive AgentsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedIsraelAdultRisk FactorsMass Screening

Stichwörter der Autor:innen

Antiviral prophylaxisHBV reactivationHepatitis B screeningImmunosuppressive therapyRituximab

Substanzen

RituximabAntiviral AgentsImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Hillel Yaffe Medical Center, Hadera, Israel.
  • Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
  • Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel. Mifleh.rt.1989@gmail.com.
  • Clalit Health Services, Tel Aviv, Israel. Mifleh.rt.1989@gmail.com.
  • , Reine, Israel. Mifleh.rt.1989@gmail.com.
  • Gastroenterology Department, Emek Medical Center, 1834111, Afula, Israel.

Förderung

  • Bar-Ilan University

Zitieren

APA

Baker, F. A., Tatour, M., Yehya, A., Saadi, T., & Hazzan, R. (2026). Hepatitis B Screening, Antiviral Prophylaxis, and Reactivation Risk in Rituximab-Treated Patients: A 17-Year Population-Based Cohort Study Highlighting Current Practices and Gaps. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-026-09998-0

Vancouver

Baker FA, Tatour M, Yehya A, Saadi T, Hazzan R. Hepatitis B Screening, Antiviral Prophylaxis, and Reactivation Risk in Rituximab-Treated Patients: A 17-Year Population-Based Cohort Study Highlighting Current Practices and Gaps. Digestive Diseases and Sciences. 2026. doi:10.1007/s10620-026-09998-0

BibTeX
@article{Baker2026,
  author = {Baker, Fadi Abu and Tatour, Mifleh and Yehya, Ahmad and Saadi, Tarek and Hazzan, Rawi},
  title = {Hepatitis B Screening, Antiviral Prophylaxis, and Reactivation Risk in Rituximab-Treated Patients: A 17-Year Population-Based Cohort Study Highlighting Current Practices and Gaps},
  journal = {Digestive Diseases and Sciences},
  year = {2026},
  doi = {10.1007/s10620-026-09998-0}
}
Kostenlos starten →